Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD -study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Krause T, Hoffstadt M, Ehehalt R, Trentmann L, Schweitzer A, Jessen P, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: plachta danielzik s. Aliment Pharmacol Ther. 2023 Aug;58(4):429-442. doi: 10.1111/apt.17616. Epub 2023 Jun 15. Aliment Pharmacol Ther. 2023. PMID: 37322825
Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Mohl W, Teich N, Hoffstadt M, Schweitzer A, von der Ohe M, Gauss A, Atreya R, Krause T, Blumenstein I, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: plachta danielzik s. Inflamm Bowel Dis. 2023 Nov 2;29(11):1741-1750. doi: 10.1093/ibd/izac271. Inflamm Bowel Dis. 2023. PMID: 36633301
Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Helwig U, Teich N, Schmidt C, Hartmann P, Sobotzki C, Schreiber S. Bokemeyer B, et al. Among authors: plachta danielzik s. Aliment Pharmacol Ther. 2023 Jul;58(1):35-47. doi: 10.1111/apt.17512. Epub 2023 Apr 13. Aliment Pharmacol Ther. 2023. PMID: 37051808
Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Hoffstadt M, Krause T, Schweitzer A, Schnoy E, Atreya R, Teich N, Trentmann L, Ehehalt R, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: plachta danielzik s. Inflamm Bowel Dis. 2024 May 2;30(5):746-756. doi: 10.1093/ibd/izad138. Inflamm Bowel Dis. 2024. PMID: 37523666
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBDBIO-ASSIST study).
Bokemeyer B, Plachta-Danielzik S, Steiner IM, Pohlschneider D, Urzica E, Hartmann P, Zemke J, Tappe U, Schreiber S, Steinkat N, Langbrandtner J, Hüppe A, Stargardt T. Bokemeyer B, et al. Among authors: plachta danielzik s. Aliment Pharmacol Ther. 2024 May;59(9):1082-1095. doi: 10.1111/apt.17926. Epub 2024 Mar 1. Aliment Pharmacol Ther. 2024. PMID: 38429885 Clinical Trial.
51 results